UBS Group
OTLK icon

UBS Group’s Outlook Therapeutics OTLK Stock Holding History

UBS Group’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.4K Sell
133,069
-76,471
-36% -$33K ﹤0.01% 7745
2025
Q4 		$331K Buy
209,540
+161,426
+336% +$258K ﹤0.01% 6303
2025
Q3 		$51K Sell
48,114
-7,010
-13% -$12.1K ﹤0.01% 7552
2025
Q2 		$88.2K Sell
55,124
-39,479
-42% -$62.9K ﹤0.01% 7334
2025
Q1 		$115K Sell
94,603
-192,041
-67% -$337K ﹤0.01% 6941
2024
Q4 		$542K Buy
286,644
+279,488
+3,906% +$1.15M ﹤0.01% 5777
2024
Q3 		$38.2K Buy
7,156
+4,746
+197% +$34.7K ﹤0.01% 6993
2024
Q2 		$17.8K Sell
2,410
-6,913
-74% -$55.5K ﹤0.01% 7375
2024
Q1 		$111K Buy
9,323
+3,032
+48% +$24.5K ﹤0.01% 6181
2023
Q4 		$49.6K Buy
+6,291
New +$53.2K ﹤0.01% 6541
2023
Q3 		– Sell
-252
Closed -$8.76K – 9835
2023
Q2 		$8.76K Sell
252
-204
-45% -$5.56K ﹤0.01% 7214
2023
Q1 		$9.94K Sell
456
-453
-50% -$10.1K ﹤0.01% 7620
2022
Q4 		$19.6K Buy
+909
New +$19.8K ﹤0.01% 7669
2022
Q3 		– Sell
-72
Closed -$1K – 10762
2022
Q2 		$1K Sell
72
-65
-47% -$1.87K ﹤0.01% 9926
2022
Q1 		$5K Sell
137
-1,457
-91% -$45.5K ﹤0.01% 9149
2021
Q4 		$43K Buy
+1,594
New +$56.9K ﹤0.01% 7050
2021
Q3 		– Sell
-254
Closed -$13K – 9924
2021
Q2 		$13K Sell
254
-89
-26% -$4.13K ﹤0.01% 7795
2021
Q1 		$15K Sell
343
-107
-24% -$4.1K ﹤0.01% 7630
2020
Q4 		$12K Buy
450
+76
+20% +$1.59K ﹤0.01% 7349
2020
Q3 		$5K Sell
374
-76
-17% -$1.69K ﹤0.01% 7321
2020
Q2 		$12K Buy
450
+441
+4,900% +$7.86K ﹤0.01% 6893
2020
Q1 		$0 Hold
9
– – ﹤0.01% 8273
2019
Q4 		$0 Sell
9
-177
-95% -$4.12K ﹤0.01% 8322
2019
Q3 		$5K Sell
186
-97
-34% -$3.74K ﹤0.01% 7480
2019
Q2 		$11K Buy
283
+274
+3,044% +$12.8K ﹤0.01% 7021
2019
Q1 		$1K Hold
9
– – ﹤0.01% 7554
2018
Q4 		$1K Sell
9
-42
-82% -$5.17K ﹤0.01% 7908
2018
Q3 		$7K Sell
51
-12
-19% -$1.69K ﹤0.01% 7338
2018
Q2 		$8K Sell
63
-10
-14% -$1.47K ﹤0.01% 7264
2018
Q1 		$10K Buy
73
+30
+70% +$5.36K ﹤0.01% 6867
2017
Q4 		$9K Buy
43
+28
+187% +$5.81K ﹤0.01% 7098
2017
Q3 		$4K Buy
15
+3
+25% +$546 ﹤0.01% 7317
2017
Q2 		$2K Hold
12
– – ﹤0.01% 7390
2017
Q1 		$5K Sell
12
-6
-33% -$2.98K ﹤0.01% 6989
2016
Q4 		$9K Buy
18
+5
+38% +$2.8K ﹤0.01% 6979
2016
Q3 		$8K Buy
13
+4
+44% +$2.54K ﹤0.01% 6918
2016
Q2 		$5K Buy
+9
New +$5.37K ﹤0.01% 7127

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

UBS Group's OTLK Position: Q1 2026 in Review

UBS Group reduced its Outlook Therapeutics (OTLK) stake by 36% in Q1 2026, selling an estimated $33K and leaving 133,069 shares worth $27.4K. The position accounts for ﹤0.01% of the portfolio, ranked #7745.

UBS Group first reported a position in OTLK in Q2 2016 and has held it in 37 quarters since. The position peaked at $542K in Q4 2024. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • UBS Group held 133,069 shares of Outlook Therapeutics worth $27.4K as of Q1 2026.
  • UBS Group sold 76,471 Outlook Therapeutics shares in Q1 2026, an estimated $33K.
  • Outlook Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7745 holding.
  • UBS Group first reported a position in Outlook Therapeutics in Q2 2016 and has held it in 37 quarters since.
  • UBS Group's Outlook Therapeutics position peaked at $542K in Q4 2024.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.